Positive top-line results from phase III study of Abrysvo in adults aged 18 to 59 at increased risk for RSV disease – Pfizer
Pfizer Inc. announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase III clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of… read more.
